---
title: Novel Treatment Strategies for Chronic Myeloid Leukemia
date: '2024-12-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39729529/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241228170644&v=2.18.0.post9+e462414
source: Blood
description: Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned
  chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition.
  As patients with access to advanced CML care have an almost normal life expectancy,
  there is a perception that CML is a problem of the past, and one should direct research
  resources elsewhere. However, a closer look at the current CML landscape reveals
  a more nuanced picture. Most patients still require life-long TKI therapy to avoid
  ...
disable_comments: true
---
Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care have an almost normal life expectancy, there is a perception that CML is a problem of the past, and one should direct research resources elsewhere. However, a closer look at the current CML landscape reveals a more nuanced picture. Most patients still require life-long TKI therapy to avoid ...